To learn how cell cultured human milk is produced and how it compares to mothers’ milk, Technology Networks spoke to Shayne Guiliano, CEO of 108Labs. In this interview, Shayne also highlights the impact that scaling up the technology will have and shares his thoughts on what could be in store for the future of cellular agriculture.

There is increasing interest in finding and applying prediction models that are more physiologically relevant to humans, in particular those which can be used for the safety assessment of new drug candidates in more vulnerable patients. Rather than starting from a healthy animal or using animal models of disease, the use of patient tissues represents a major step forward.

In this interview, Dr. George Emanuel discusses some of the most exciting findings from the Mouse Receptor Map and highlights how the datasets will benefit the Human Cell Atlas project.

Technology Networks spoke to John Moore, president of Scientific Bioprocessing to find out more about the monitoring of cell cultures in real-time using optical sensors.

To learn more about the causes and consequences of peripheral nerve damage and some of the solutions available to patients, Technology Networks spoke with Karen Zaderej, chief executive officer of Axogen.

Technology Networks recently had the pleasure of speaking with ImVitro’s CEO and founder, Dr Alexandra Boussommier-Calleja, to learn more about IVF and how artificial intelligence (AI) could help to address some of the challenges associated with the technique.

Many of us are familiar with the undesirable physical and mental effects of a disrupted sleep/wake cycle caused by traveling across multiple time zones or working irregular hours. A collaborative project designed to address these issues is working to develop a “living pharmacy” – a personalized, wireless and fully implantable device that can control the body’s circadian clock.

We spoke with Archie Cullen, senior vice president and head of bioscience solutions, Lonza. In this interview, Archie discusses the evolution of the Nucleofector® Technology, highlighting how it has supported and propelled basic and applied research. He also explores some of the most recent developments in the Nucleofector® Platform’s exciting journey.

The biotechnology company Angany recently announced the successful production of neutralizing monoclonal antibodies (NAbs) derived from the plasma of COVID-19 patients using its plant-based system. Angany has now joined forces with global technology company Phylloceuticals to leverage its plant-made commercial production system, to rapidly scale up commercial manufacturing.

To learn about some of the main challenges associated with generating a large library of edited iPSCs and the role that Synthego is playing in the iNDI project, we spoke to Synthego’s CSO, Dr Robert Dean.